Phibro Animal Health (NASDAQ:PAHC) Hits New 1-Year High – Should You Buy?
by Scott Moore · The Cerbat GemPhibro Animal Health Corporation (NASDAQ:PAHC – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $58.84 and last traded at $58.1680, with a volume of 329 shares. The stock had previously closed at $55.66.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on PAHC. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Finally, Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.50.
View Our Latest Report on Phibro Animal Health
Phibro Animal Health Stock Up 4.9%
The business’s fifty day moving average is $51.09 and its two-hundred day moving average is $44.10. The company has a market cap of $2.37 billion, a P/E ratio of 26.06, a price-to-earnings-growth ratio of 0.85 and a beta of 0.69. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05.
Phibro Animal Health (NASDAQ:PAHC – Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The company had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current year.
Phibro Animal Health Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th were issued a dividend of $0.12 per share. The ex-dividend date was Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a yield of 0.8%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 21.33%.
Insiders Place Their Bets
In other news, CEO Jack Bendheim sold 7,040 shares of the business’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $52.52, for a total value of $369,740.80. Following the completion of the sale, the chief executive officer owned 73,320 shares in the company, valued at approximately $3,850,766.40. The trade was a 8.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 316,472 shares of company stock worth $15,265,419. Company insiders own 50.13% of the company’s stock.
Institutional Investors Weigh In On Phibro Animal Health
Large investors have recently modified their holdings of the business. Penserra Capital Management LLC bought a new stake in shares of Phibro Animal Health in the 3rd quarter valued at about $519,000. Capricorn Fund Managers Ltd bought a new stake in shares of Phibro Animal Health in the 3rd quarter valued at about $10,233,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Phibro Animal Health in the 3rd quarter valued at about $8,931,000. Citigroup Inc. raised its holdings in shares of Phibro Animal Health by 112.3% in the 3rd quarter. Citigroup Inc. now owns 54,941 shares of the company’s stock valued at $2,223,000 after purchasing an additional 29,066 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Phibro Animal Health in the 2nd quarter valued at about $813,000. Institutional investors own 99.34% of the company’s stock.
About Phibro Animal Health
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.